



16th  
**ICML**  
Virtual Edition

**International  
Conference  
on Malignant  
Lymphoma**  
Lugano

June  
18-22  
2021

# 16-ICML SCIENTIFIC PROGRAM

Updated on May 11

Organized by



In cooperation with



American Association  
for Cancer Research<sup>®</sup>

FINDING CURES TOGETHER<sup>™</sup>



# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Saturday, June 19

Channel	Time	Session	Article/ abstract nr.
	<b>13:00 – 13:45</b>	<b>“Meet the Professor” session</b>	
		What's new in peripheral T-cell lymphomas	EB 06
		Stefano Luminari, Reggio Emilia (Italy)	
		Live Q&A	
	<b>13:00 – 13:45</b>	<b>“Meet the Professor” session</b>	
		Cutaneous T-cell lymphomas – an update 2021	EB 05
		Werner Kempf, Zürich (CH)	
		Live Q&A	
	<b>13:00 – 13:45</b>	<b>“Meet the Professor” session</b>	
		Personalised medicine for Hodgkin Lymphoma: mitigating toxicity while preserving cure	EB 04
		Peter W.M. Johnson, Southampton (UK)	
		Live Q&A	
	<b>13:00 – 13:45</b>	<b>“Meet the Professor” session</b>	
		Use of available prognostic scores in treatment decision: beyond standard prognostic scores to include molecular/ genetics/imaging	
		John F. Seymour, Melbourne (Australia)	
		Live Q&A	
	<b>14:00 – 15:00</b>	<b>Opening of the conference</b>	
		Welcome to attendees	
		Franco Cavalli, Bellinzona (Switzerland)	
		<b>Henry Kaplan Memorial Lecture and ICML Prize</b>	
		Laudatio: Franco Cavalli, Bellinzona (Switzerland)	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Saturday, June 19

Channel	Time	Session	Article/ abstract nr.
	14:00 – 15:00	Towards control of chronic lymphocytic leukemia with targeted agents Michael Hallek, Cologne (Germany)	001
	15:15 – 16:45	<b>Plenary session</b> Co-chairs: James Armitage, Omaha, NE (USA) and Franco Cavalli, Bellinzona (Switzerland)	
		Pervasive Hypermutation of Super-enhancer Regions Dysregulates Oncogene Expression in Diffuse Large B-cell Lymphoma Elodie Bal, New York, NY (USA)	004
		Introduced by Ralf Küppers, Essen (Germany)	
		Live Q&A moderated by session chairs	
		Early Positron Emission Tomography Response-Adapted Treatment in Localized Diffuse Large B-Cell Lymphoma (aaIPI=0): Results of the Phase 3 LYSA LNH 09-1B Trial. Serge Bologna, Essey lès Nancy (France)	005
		Introduced by Jonathan W. Friedberg, Rochester, NY (USA)	
		Live Q&A moderated by session chairs	
		Determinants of resistance to engineered T-cell therapies targeting CD19 in lymphoma Brian Sworder, Stanford, CA (USA)	006
		Introduced by Stephen J. Schuster, Philadelphia, PA (USA)	
		Live Q&A moderated by session chairs	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Saturday, June 19

Channel	Time	Session	Article/ abstract nr.
	<b>17:00 – 18:15</b>	<b>AACR-ICML joint session</b>	
		<b>Artificial intelligence in lymphoma diagnosis and treatment</b>	
		Co-chairs: Riccardo Dalla-Favera, New York, NY (USA), Bertrand Nadel, Marseille (France) and Olivier Elemento, New York, NY (USA)	
		Artificial intelligence and medicine: past and future	007
		Luca M. Gambardella, Lugano (Switzerland)	
		Artificial intelligence and pathology	008
		Pierre Brousset, Toulouse (France)	
		Use of deep learning to analyse and exploit molecular data	009
		Dan A. Landau, New York, NY (USA)	
		How machine learning can enhance clinical development	010
		Paul Trichelair, Paris (France)	
		Live Q&A moderated by session chairs	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

**Sunday, June 20**

Channel	Time	Session	Article/ abstract nr.
	<b>12:00 – 13:30</b>	<b>UCLI-ICML joint session</b>	
		<b>New data on T-cell and other lymphomas</b>	
		Honorary co-chairs: Franco Cavalli, Bellinzona (Switzerland) and Jun Ma, Harbin (China)	
		Executive co-chairs: Stefano Luminari, Reggio Emilia (Italy) and Jun Zhu, Beijing (China)	
		Welcome	
		Jun Zhu, Beijing (China)	
		T-cell lymphoma biopathology: what is new?	
		Laurence de Leval, Lausanne (Switzerland)	
		The epidemiology of malignant lymphoid diseases in China	
		Yu-qin Song, Beijing (China)	
		Recent advances in Extranodal Natural Killer/T-Cell Lymphoma: experiences from the SYSUCC	
		Qing-qing Cai, Guangzhou (China)	
		New treatment options in T-cell lymphoma	
		Stefano Luminari, Reggio Emilia (Italy)	
		The changing faces of EBV+ T/NK-cell lymphomas: diagnostic challenges and advances	
		Xiao-qiu Li, Shanghai (China)	
		Closure	
		Stefano Luminari, Reggio Emilia (Italy)	
	<b>12:30 – 13:30</b>	<b>“Innovation in radiotherapy – new dose/fractionation schedules”</b>	
		Workshop organised by the International Lymphoma Radiation Oncology Group (ILROG)	
		Chair: Lena Specht, Copenhagen (Denmark)	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
	12:30 – 13:30	Radiation doses in the treatment of lymphomas – what is the evidence? Peter Hoskin, Manchester (UK)	
		Low-dose regimens – new fractionation schemes for indolent lymphomas Joachim Yahalom, New York, NY (USA)	
		Fewer but larger fractions in lymphoma radiotherapy – experience from the COVID emergency fractionation Lena Specht, Copenhagen (Denmark)	
	14:00 – 14:45	<b>Gianni Bonadonna Memorial Lecture</b> (in collaboration with American Association for Cancer Research, AACR) Laudatio: Davide Rossi, Bellinzona (Switzerland)	
		The architecture of liquid biopsy research for lymphoma monitoring Ash A. Alizadeh, Stanford, CA (USA)	002
	15:00 – 16:30	<b>Educational symposium on High risk follicular lymphoma</b> Chair: Brad Kahl, Saint Louis, MO (USA)	
		Upfront identification of high risk follicular lymphoma Carla Casulo, Rochester, NY (USA)	EB 12
		Vulnerabilities in the tumor and microenvironment in follicular lymphoma Elias Campo, Barcelona (Spain)	EB 11
		High risk follicular lymphoma: treatment options Brad Kahl, Saint Louis, MO (USA)	EB 13
		Live Q&A moderated by session chair	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
	<b>16:45 – 17:15</b>	<b>“Meet the Professor” session</b>	
		Molecular diagnostics and reporting in lymphoid malignancies: current status and beyond	EB 09
		Richard Rosenquist Brandell, Stockholm (Sweden)	
		Live Q&A	
	<b>16:45 – 17:15</b>	<b>“Meet the Professor” session</b>	
		New drugs and pharmacological interactions in real life	EB 10
		Anastasios Stathis, Bellinzona (CH)	
		Live Q&A	
	<b>16:45 – 17:30</b>	<b>“Meet the Professor” session</b>	
		Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches	EB 03
		Martin Dreyling, Munich (Germany)	
		Live Q&A	
	<b>16:45 – 17:30</b>	<b>“Meet the Professor” session</b>	
		Recognizing but not harming. Borderline B-cell lymphoid proliferations	EB 07
		Leticia Quintanilla-Martinez de Fend, Tübingen (Germany)	
		Live Q&A	
	<b>17:45 – 19:15</b>	<b>Session 1: NEW THERAPEUTICS</b>	
		Co-chairs: Francesco Bertoni, Bellinzona (Switzerland) and Gilles Salles, New York, NY (USA)	
		Targeting proximal BCR signaling pathway in diffuse large B-cell lymphoma	011
		Jae Woo Choi, Bethesda, MD (USA)	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
	17:45 – 19:15	MALT1 degradation for the treatment of Activated B-Cell type Diffuse Large B-cell Lymphoma Madhav Seshadri, New York, NY (USA)	012
		KT-413, a novel IRAKIMiD Degradator of IRAK4 and IMiD substrates, has a differentiated MOA that leads to single-agent and combination regressions in MYD88MT Lymphoma models Michele Mayo, Watertown, MA (USA)	013
		Live Q&A moderated by session chairs	
		First-in-human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS-3201b) in patients with relapsed or refractory non-Hodgkin lymphomas Kenj Ishitsuka, Kagoshima, Japan	014
		Glofitamab step-up dosing: updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients Carmelo Carlo-Stella, Milan (Italy)	015
		Subcutaneous Epcoritamab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Safety Profile and Anti-tumor Activity Martin Hutchings, Copenhagen, Denmark	016
		Live Q&A moderated by session chairs	
	17:45 – 19:15	<b>Session 2: LYMPHOMA IMAGING</b> Co-chairs: Sally F. Barrington, London (UK) and Joséé Zijlstra-Baalbergen, Amsterdam (Netherlands)	
		Defining ultra-high-risk DLBCL patients prior to initial treatment based on an integrative host and disease prognostic score (from REMARC study) Catherine Thieblemont, Paris (France)	017



# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
	17:45 – 19:15	Integration of baseline metabolic parameters and mutational profile predicts outcome in DLBCL patients. A post hoc analysis of SAKK38/07 study. Guido Ghilardi, Bellinzona (Switzerland)	018
		Baseline Metabolic Tumor Volume and IPS predict ABVD failure in advanced-stage Hodgkin Lymphoma with a negative interim PET scan after two chemotherapy cycles. A retrospective analysis from the GITIL/FIL HD0607 trial Andrea Gallamini, Nice (France)	019
		Live Q&A moderated by session chairs	
		Prognostic role of lesion dissemination feature (Dmax) calculated on baseline PET/CT in Hodgkin Lymphoma Rexhep Durmo, Modena (Italy)	020
		Predictive value of quantitative 18F-FDG-PET-CT radiomics analysis in 174 patients with relapsed/refractory classical Hodgkin lymphoma Julia Driessen, Amsterdam (Netherlands)	021
		Development and validation of a PET radiomics prognostic model for diffuse large B cell lymphoma Luca Ceriani, Bellinzona (Switzerland)	022
		Live Q&A moderated by session chairs	
	17:45 – 19:15	<b>Session 3: AGGRESSIVE LYMPHOMAS</b> Co-chairs: Peter M.W. Johnson, Southampton (UK) and Margaret Shipp, Boston, MA (USA)	
		Clonal Hematopoiesis is associated with inferior prognosis in newly diagnosed Diffuse Large B-Cell Lymphoma patients Jan L. Boegeholz, Stanford, CA (USA)	023

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
	17:45 – 19:15	Whole genome sequencing of matched primary and relapsed DLBCL reveals distinct evolutionary dynamics associated with relapse timing Laura K. Hilton, Vancouver, B.C. (Canada)	024
		Phased variants improve DLBCL minimal residual disease detection at the end of therapy David Kurtz, Stanford, CA (USA)	025
		Live Q&A moderated by session chairs	
		Genetic Subtype Guided Rituximab-based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-cell Lymphoma: First Report of a Randomized Phase 2 Study Muchen Zhang, Shanghai, China	026
		Biomarker-driven treatment strategy in high risk diffuse large B-cell lymphoma: Results of a Nordic phase 2 study Sirpa Leppä, Helsinki, Finland	027
		Long-term analyses from L-MIND, a Phase II study of tafasitamab plus lenalidomide (LEN) in patients (pts) with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) Johannes Duell, Würzburg, Germany	028
		Live Q&A moderated by session chairs	
	17:45 – 19:15	<b>Session 4: CHRONIC LYMPHOCYTIC LEUKEMIA</b> Co-chairs: Susan O'Brien, Orange, CA (USA) and Kostas Stamatopoulos, Thessaloniki (Greece)	
		Adaptation of chronic lymphocytic leukemia to ibrutinib is mediated by epigenetic plasticity of residual disease and by-pass signaling via MAPK pathway Lodovico Terzi di Bergamo, Bellinzona (Switzerland)	029

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Monday, June 21

Channel	Time	Session	Article/ abstract nr.
	17:45 – 19:15	Genetic markers and outcome with front line obinutuzumab plus either chlorambucil or venetoclax - updated analysis of the CLL14 trial	030
		Eugen Tausch, Ulm (Germany)	
		Venetoclax-obinutuzumab modulates clonal growth: Results of a population-based minimal residual disease model from the randomized CLL14 study	031
		Othman Al-Sawaf, Cologne (Germany)	
		Live Q&A moderated by session chairs	
		CAPTIVATE primary analysis of first-line treatment with fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)	032
		Constantine Tam, Melbourne (Australia)	
		First Results of a Head-to-Head Trial of Acalabrutinib versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia	033
		Peter Hillmen, Leeds (UK)	
		Bendamustine, followed by Obinutuzumab, Acalabrutinib and Venetoclax in patients (pts) with relapsed/refractory chronic lymphocytic leukemia (CLL): CLL2-BAAG trial of the GCLLSG	034
		Paula Cramer, Cologne (Germany)	
		Live Q&A moderated by session chairs	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Monday, June 21

Channel	Time	Session	Article/ abstract nr.
	<b>12:30 – 13:30</b>	<b>“The evolving role of Radiotherapy in the salvage treatment for lymphoma in the era of CAR-T therapy”</b> Workshop organised by the International Lymphoma Radiation Oncology Group (ILROG) Chair: Bouthaina S. Dabaja, Houston, TX (USA) Radiation prior to immune-cellular therapy: the science behind sublethal immunogenic cell death Bouthaina S. Dabaja, Houston, TX (USA) Optimal integration of RT in salvage therapy for relapsed / refractory lymphoma (including CAR-T) Richard Tsang, Toronto, ON (Canada) Clinical trials combining RT and CAR-T George Mikhaeel, London (UK)	
	<b>14:00 – 14:45</b>	<b>John Ultmann Memorial Lecture</b> (in collaboration with European School of Oncology, ESO) Laudatio: Emanuele Zucca, Bellinzona (Switzerland) Immune Suppression and Dysfunction in the Tumor Microenvironment in Lymphoma Stephen M. Ansell, Rochester, MN (USA)	003
	<b>15:00 – 16:30</b>	<b>Educational symposium on Immunotherapy</b> Chair: Gilles Salles, New York, NY (USA) Optimizing CAR T cell therapy in lymphoma Gilles Salles, New York, NY (USA) Allogeneic stem cell transplant in non-Hodgkin lymphomas: still an indication? Peter Dreger, Heidelberg (Germany)	EB 15 EB 14

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Monday, June 21

Channel	Time	Session	Article/ abstract nr.
	15:00 – 16:30	Bispecific Antibodies for the Treatment of Lymphomas: Promises and Challenges Stephen J. Schuster, Philadelphia, PA (USA)  Live Q&A moderated by session chair	EB 16
	16:45 – 17:45	<b>“Challenging cases” session</b> <b>Aggressive NHL</b> Chair: Franco Cavalli, Bellinzona (Switzerland) Case 1: “A patient with abdominal pain” Discussant: Ranjana H. Advani, Stanford, CA (USA) Case 2: “Can we offer a curative treatment to patients with relapsed DLBCL who are not a candidate for autologous stem cell transplant?” Discussant: Urban Novak, Bern (Switzerland) Case 3: “How should I treat patients with MCL relapsing in CNS?” Discussant: Martin Dreyling, Munich (Germany) Case 4: “A 31 year old man with dysphagia” Discussant: Pier Luigi Zinzani, Bologna (Italy)	
	16:45 – 17:45	<b>“Challenging cases” session</b> <b>Indolent NHL and CLL</b> Chair: Davide Rossi, Bellinzona (Switzerland) Case 1: “A young patient with leg swelling” Discussant: Ranjana H. Advani, Stanford, CA (USA) Case 2: “The gentleman with acid peptic disease” Discussant: Mary Gospodarowicz, Toronto, ON (Canada) Case 3: “A woman with high-risk CLL and tachycardia” Discussant: Barbara Eichhorst, Cologne (Germany) Case 4: “A young man with triple refractory CLL” Discussant: Barbara Eichhorst, Cologne (Germany)	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Monday, June 21

Channel	Time	Session	Article/ abstract nr.
	<b>16:45 – 17:45</b>	<b>“Challenging cases” session</b> <b>Hodgkin Lymphoma</b> Chair: Alden Moccia, Bellinzona (Switzerland) Case 1: “A sportsman with shortness of breath” Discussant: John Kuruville, Toronto, ON (Canada) Case 2: “A late relapse Hodgkin lymphoma” Discussant: Peter W.M. Johnson, Southampton (UK) Case 3: “A 73 year-old woman in the ER” Discussant: James O. Armitage, Omaha, NE (USA) Case 4: “A sportsman with enlarged lymph nodes” Discussants: Peter Borchmann, Cologne (Germany) and Steven Le Guill, Nantes (France)	
	<b>16:45 – 17:45</b>	<b>“Challenging cases” session</b> <b>Difficult pathology cases</b> Chair: Luca Mazzucchelli, Locarno (Switzerland)  Discussants: Stefan Dirnhofer, Basel (Switzerland) and Alexandar Tzankov, Basel (Switzerland)	
	<b>18:00 – 18:45</b>	<b>“Meet the Professor” session</b> Sequencing of myeloma therapy: finding the right path among many standards S. Vincent Rajkumar, Rochester, MN (USA)  Live Q&A	EB 08
	<b>18:00 – 18:45</b>	<b>“Meet the Professor” session</b> Langerhans Cell Histiocytosis: Version 2021 Carl E. Allen, Houston, TX (USA)  Live Q&A	EB 01

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Monday, June 21

Channel	Time	Session	Article/ abstract nr.
	<b>18:00 – 18:45</b>	<b>“Meet the Professor” session</b> Molecular classification of aggressive lymphomas – past, present, future Björn Chapuy, Göttingen (Germany) Live Q&A	EB 02
	<b>18:00 – 18:45</b>	<b>IBSA Foundation Special Forum</b> Welcome Silvia Misiti, Lugano (Switzerland) Introduction Andrea Alimonti, Bellinzona (Switzerland) Vaccines and monoclonals to regain our freedom Rino Rappuoli, Siena (Italy)	
	<b>19:00 – 20:00</b>	<b>THE BIG DEBATE: “DLBCL: one disease, one treatment?”</b> organized by the Oncology Institute of Southern Switzerland (IOSI) (supported by an unrestricted educational grant from GILEAD SCIENCES) Chair: Emanuele Zucca, Bellinzona (Switzerland) <b>DEBATE 1:</b> Are we ready to introduce genetic classification in routine diagnostics? <b>YES.</b> Treatment improvement will not be possible otherwise. Björn Chapuy, Göttingen (Germany) <b>NO.</b> This is not yet feasible in everyday community settings. Leticia Quintanilla Martinez – de Fend, Tübingen (Germany) <b>DEBATE 2:</b> Is frontline R-CHOP still the sole standard? <b>YES.</b> R-CHOP21 remains the standard of care. Laurie Sehn, Vancouver B.C. (Canada) <b>NO.</b> We have already moved beyond R-CHOP.	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

**Monday, June 21**

Channel	Time	Session	Article/ abstract nr.
	<b>19:00 – 20:00</b>	Grzegorz S. Nowakowski, Rochester, MN (USA)	
		<b>DEBATE 3:</b> Will targeted treatments soon inform frontline management?	
		<b>YES.</b> Precision medicine will allow patient-tailored treatment. Margaret Shipp, Boston, MA (USA)	
		<b>NO.</b> CART and agnostic immunotherapies will replace chemotherapy. Stephen J. Schuster, Philadelphia, PA (USA)	
	<b>19:00 – 20:30</b>	<b>Session 5 : PEDIATRIC LYMPHOMAS</b>	
		Chair: Wilhelm Wössmann, Hamburg (Germany)	
		Current Status and Challenges in Diagnosis of Childhood NHL Wolfram Klapper, Kiel (Germany)	035
		Dose-adjusted EPOCH-rituximab or intensified B-NHL-BFM-type Therapy for Pediatric Primary Mediastinal B-cell Lymphoma Fabian Knörr, Hamburg (Germany)	036
		An Open-label, Phase 1/2 Study of Frontline Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Paediatric Patients with Advanced Stage Hodgkin Lymphoma Anna Franklin, Aurora, CO (USA)	
		Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYAs) with Stage III or IV Hodgkin Lymphoma: a Subgroup Analysis From the Phase 3 ECHELON-1 Study Howland Crosswell, Greenville, SC (USA)	037
		A UK population-based study of non-Hodgkin Lymphoma in Teenagers and Young Adults (TYA) - Incidence, treatment and outcomes Robert Carr, London (UK)	039
		Live Q&A moderated by session chair	



# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
	<b>13:00 – 14:30</b>	<b>Session 6: LYMPHOMA BIOLOGY 1</b>	
		Co-chairs: Elias Campo, Barcelona (Spain) and Ari M. Melnick, New York, NY (USA)	
		Molecular Subclusters of Follicular Lymphoma: a report from the UK's Haematological Malignancy Research Network	040
		Reuben Tooze, Leeds (UK)	
		Somatic Alterations in Follicular Lymphoma Associate with unique Tumor-Cell Transcriptional States and Tumor-Immune Microenvironments.	041
		Jordan Krull, Rochester, MN (USA)	
		CREBBP mediated acetylation of KMT2D in normal and transformed GC B cells	042
		Sofija Vlasevska, New York, NY (USA)	
		Live Q&A moderated by session chairs	
		Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma	043
		Davide Rossi, Bellinzona (Switzerland)	
		Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL): clinico-pathological analysis of a multicenter European cohort.	044
		Doriane Cavalieri, Clermont-Ferrand, France	
		RHOA G17V potentiates CD28 T195P mutation induced NFAT transcriptional activity upon CD3/CD28 stimulation	045
		David Vallois, Lausanne (Switzerland)	
		Live Q&A moderated by session chairs	
	<b>13:00 – 14:30</b>	<b>Session 7: AGGRESSIVE EXTRANODAL ENTITIES</b>	
		Co-chairs: Mary K. Gospodarowicz, Toronto, ON (Canada) and Grzegorz S. Nowakowski, Rochester, MN (USA)	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
	13:00 – 14:30	Noninvasive detection, classification, and risk stratification of primary CNS lymphomas by ctDNA profiling Jurik A. Mutter, Freiburg (Germany)	046
		MATRIX induction followed by autologous stem cell transplant or whole-brain irradiation in primary CNS lymphoma. 7-year results of the IELSG32 randomized trial. Andrés J.M. Ferreri, Milan (Italy)	047
		Intensified (intravenous and intrathecal) CNS prophylaxis in primary testicular diffuse large B-cell lymphoma: 5-year results of the IELSG30 trial. Annarita Conconi, Biella (Italy)	048
		Live Q&A moderated by session chairs	
		Impact of different induction regimens on the outcome of primary mediastinal B cell lymphoma in the prospective IELSG 37 trial Emanuele Zucca, Bellinzona (Switzerland)	049
		Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study Vincent Camus, Rouen (France)	050
		Nivolumab plus brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: Extended follow-up from the phase 2 CheckMate 436 study Pier Luigi Zinzani, Bologna (Italy)	051
		Live Q&A moderated by session chairs	
	13:00 – 14:30	<b>Session 8: PERIPHERAL T/NK-CELL LYMPHOMAS</b> Co-chairs: Stefano Luminari, Reggio Emilia (Italy) and Julie M. Vose, Omaha, NE (USA)	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

**Tuesday, June 22**

Channel	Time	Session	Article/ abstract nr.
	<b>13:00 – 14:30</b>	ESA versus MESA with sandwiched radiotherapy in patients with early-stage natural killer/T-cell lymphoma: a multicentre, randomised, phase 3, non-inferiority trial Hui-Juan Zhong, Shanghai (China)	052
		Allogeneic hematopoietic cell transplantation for peripheral T-cell lymphoma: Comparable outcomes of haplo-identical vs. matched donors. A CIBMTR & EBMT Analysis Peter Dreger, Heidelberg (Germany)	053
		Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial Martine Bagot, Paris (France)	054
		Live Q&A moderated by session chairs	
		Multi-center phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL) Jia Ruan, New York, NY (USA)	055
		The Combination of Duvelisib and Romidepsin (DR) Is Highly Active Against Relapsed/Refractory Peripheral T-cell Lymphoma with Low Rates of Transaminitis: Final Results Steven M. Horwitz, New York, NY (USA)	056
		Early Safety and Efficacy Data from a Phase I/II Trial of DZD4205, a Selective JAK1 Inhibitor, in Relapsed/Refractory Peripheral T-Cell Lymphoma Won-Seog Kim, Seoul (South Korea)	057
		Live Q&A moderated by session chairs	
	<b>13:00 – 14:30</b>	<b>Session 9: MANTLE CELL LYMPHOMA</b> Co-chairs: Martin Dreyling, Munich (Germany) and John P. Leonard, New York, NY (USA)	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
	13:00 – 14:30	A simple epigenetic signature defines two biologic groups of mantle cell lymphoma Marco M. Bühler, Barcelona (Spain)	058
		A completely genetic prognostic model overcomes clinical prognosticators in mantle cell lymphoma: results from the MCL0208 trial from the Fondazione Italiana Linfomi (FIL) Simone Ferrero, Turin (Italy)	059
		Efficacy and safety of ibrutinib in combination with rituximab as frontline treatment for indolent clinical forms of mantle cell lymphoma. Results of the GELTAMO IMCL-2015 study Eva Giné, Barcelona (Spain)	060
		Live Q&A moderated by session chairs	
		The combination of venetoclax, lenalidomide and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability. Tycel J. Phillips, Ann Arbor, MI (USA)	061
		SAKK 36/13 - Ibrutinib plus bortezomib and ibrutinib maintenance for relapsed and refractory mantle cell lymphoma: final report of a Phase I/II trial of the European MCL network Urban Novak, Bern (Switzerland)	062
		MCL Induction R <sup>2</sup> followed by maintenance in patients with relapsed/refractory mantle cell lymphoma: Interim analysis from the Phase 3b MAGNIFY study Jeff P. Sharman, Eugene, OR (USA)	063
		<b>14:45 – 16:15</b>	<b>Session 10: LYMPHOMA BIOLOGY 2</b> Co-chairs: Ralf Küppers, Essen (Germany) and Laura Pasqualucci, New York, NY (USA)

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
	14:45 – 16:15	The topology of MYC rearrangements in double-hit lymphoma is constrained by the preceding IGH-BCL2 rearrangement – an LLMP project Laura K. Hilton, Vancouver, B.C. (Canada)	064
		The mutational landscape of double/triple-hit high-grade B-cell lymphoma with BCL2 rearrangement (DH/TH-BCL2) – an LLMP project Brett J. Collinge, Vancouver, B.C. (Canada)	065
		Do Cell-of-Origin, Double Expresser, and Double Hit Status Affect Outcomes in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL)? A Prospective Observational Study. Sanjal H. Desai, Rochester, MN (USA)	066
		Live Q&A moderated by session chairs	
		Copy number variation analysis identifies distinct genomic features in adult Burkitt lymphoma Kostiantyn Dreval, Burnaby, B.C. (Canada)	067
		Key genetic and molecular aberrations identified in both adult and EBV-positive Burkitt lymphoma patients Nicole Thomas, Burnaby, B.C. (Canada)	068
		Triple positive (CD10+BCL6+MUM1+) diffuse large B-cell lymphomas in adults are a heterogeneous group enriched in large B-cell lymphomas with IRF4 rearrangement Leonie Frauenfeld, Tübingen (Germany)	069
		Live Q&A moderated by session chairs	
	14:45 – 16:15	<b>Session 11: HODGKIN LYMPHOMA</b> Co-chairs: Ranjana H. Advani, Stanford, CA (USA) and Bruce D. Cheson, Washington, D.C. (USA)	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
	14:45 – 16:15	Circulating tumor DNA is a prognostic biomarker in classic Hodgkin lymphoma Maria Cristina Piroso, Bellinzona (Switzerland)	070
		Relapses in interim PET-negative limited-stage Hodgkin lymphoma patients receiving ABVD with or without radiotherapy – Analysis of EORTC/FIL/LYSA H10 and UK NCRI RAPID trials Igor Aurer, Zagreb (Croatia)	071
		CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL). Ann S. LaCasce, Boston, MA (USA)	072
		Live Q&A moderated by session chairs	
		New prognostic score incorporating MTV predicts treatment failure in advanced Hodgkin Lymphoma Sally F. Barrington, London (UK)	073
		Nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous transplantation: 5-year overall survival from the phase 2 CheckMate 205 study Stephen M. Ansell, Rochester, MN (USA)	074
		Camidanlumab Tesirine Efficacy and Safety in an Open-label, Multicenter, Phase 2 Study of Patients (pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL) Pier Luigi Zinzani, Bologna (Italy)	075
		Live Q&A moderated by session chairs	
	14:45 – 16:15	<b>Session 12: INDOLENT LYMPHOMAS</b> Co-chairs: Carla Casulo, Rochester, NY (USA) and T. Andrew Lister, London (UK)	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

**Tuesday, June 22**

Channel	Time	Session	Article/ abstract nr.
	14:45 – 16:15	Intratumoral T-cells have a Differential Impact on FDG-PET Parameters in Follicular Lymphoma Karthik Nath, Brisbane (Australia)	076
		Direct-acting antivirals as primary treatment for HCV-associated indolent non-Hodgkin Lymphomas: the prospective BArT study of the Fondazione Italiana Linfomi Michele Merli, Varese (Italy)	077
		Primary extranodal follicular lymphoma in a large retrospective survey of the International Extranodal Lymphoma Study Group (IELSG31) Annarita Conconi, Biella (Italy)	078
		Live Q&A moderated by session chairs	
		Phase II trial of rituximab plus chlorambucil followed by a 2-year subcutaneous rituximab maintenance in MALT lymphoma patients (IELSG38) Maria Cristina Piroso, Bellinzona (Switzerland)	079
		Response adapted post induction therapy in follicular lymphoma: updated results of the FOLL12 trial by the Fondazione Italiana Linfomi (FIL). Stefano Luminari, Reggio Emilia (Italy)	080
		Immune Priming with Nivolumab followed by Nivolumab & Rituximab in 1st Line Treatment of Follicular Lymphoma: The Phase 2 1st FLOR Study Eliza A. Hawkes, Melbourne (Australia)	081
		Live Q&A moderated by session chairs	
	<b>14:45 – 16:15</b>	<b>Session 13: CAR-T CELL THERAPY</b> Co-chairs: Paolo Corradini, Milan (Italy) and Peter Dreger, Heidelberg (Germany)	

# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

**Tuesday, June 22**

Channel	Time	Session	Article/ abstract nr.
	14:45 – 16:15	CAR-HEMATOTOX: A discriminative model for CAR T-cell related hematotoxicity in relapsed/refractory large B-cell lymphoma	082
		Kai Rejeski, Munich (Germany)	
		Early PET response predicts outcome in large B-cell lymphoma patients treated with CD19 CAR-T	083
		Maria Cuadrado, London (UK)	
		First results of DLBCL patients treated with CAR-T cells and enrolled in DESCAR-T registry, a French real-life database for CAR-T cells in hematologic malignancies.	084
		Steven Le Gouill, Nantes (France)	
		Live Q&A moderated by session chairs	
		Efficacy and Safety of Tisagenlecleucel (Tisa-cel) in Adult Patients (Pts) With Relapsed/Refractory Follicular Lymphoma (r/r FL): Primary Analysis of the Phase 2 ELARA Trial	085
		Nathan H. Fowler, Philadelphia, PA (USA)	
		TRANSCEND CLL 004: Phase 1 cohort of Lisocabtagene Maraleucel (liso-cel) combined with Ibrutinib (ibr) for patients (pts) with R/R CLL/SLL	086
		William G. Wierda, Houston, TX (USA)	
		Outcome of large B-cell lymphoma patients failing CD19 targeted CAR-T therapy	087
		Andrea Kuhn, London (UK)	
		Live Q&A moderated by session chairs	
	16:30 – 17:00	<b>Special Lecture: Lymphoma Treatment in Developing Countries</b>	088
		Chair: Franco Cavalli, Bellinzona (Switzerland)	
		Andrea Biondi, Monza (Italy)	



# SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

## Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
	<b>17:00 – 17:30</b>	<b>Take Home Messages</b>	
		James O. Armitage, Omaha, NE (USA)	
		Closure and Farewell	
		Franco Cavalli, Bellinzona (Switzerland)	